<DOC>
	<DOCNO>NCT02531672</DOCNO>
	<brief_summary>The purpose study use new image drug call 11C-choline used PET/CT scan see prostate cancer see well scan , bone scan , CT MRI .</brief_summary>
	<brief_title>Detecting Recurrent Prostate Cancer With 11C-choline Positron Emission Tomography</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Choline</mesh_term>
	<criteria>Patient must biopsyproven adenocarcinoma prostate initially treat curative intent ( surgery radiation therapy common treatment treatment also eligible ) . Biochemical recurrence define follow : 1 . PSA ≥ 0.2 ng/mL least two sequential test patient treat surgery . 2 . PSA ≥ 0.2 ng/mL post therapy nadir patient treat radiation therapy , brachytherapy cryotherapy . 3 . PSA ≥ 0.2 ng/ml recent therapy nadir patient receive additional treatment recurrent set Patient must undergo standardofcare restaging clearly identify site ( ) active disease , prior study must show equivocal finding workup consider necessary make clinical decision . Standard stag examination may include one follow : CT MRI , bone imaging ( either Tc99m bisphosphonate scintigraphy MDP F18 sodium fluoride PET ) , FDG PET , In111 capromab pendetide scintigraphy old 3 month consent date . Age ≥ 18 year . Patient must able tolerate PET/CT imaging . Patient must able understand willing sign write informed consent document . Patient must claustrophobia would preclude PET/CT image contraindication CT imaging .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>11C-choline</keyword>
	<keyword>Positron Emission Tomography</keyword>
	<keyword>15-117</keyword>
</DOC>